EMA begins early advice pilot to improve pediatric drug development
This article was originally published in SRA
Executive Summary
The European Medicines Agency is offering companies free early advice on the pediatric aspects of drug development, in order to help them make their development programs more efficient and ultimately speed up access to new drugs for children.
You may also be interested in...
Parallel EMA-FDA Pediatric Advice On The Cards For Companies
The European Medicines Agency is working on plans to supplement its early advice pilot on pediatric development by providing joint advice with the US FDA and, in some cases, by arranging for a three-way dialogue with companies.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.